Insurer And Patient Drug Costs Soared For Top-Sellers Over 6-Year Study
Executive Summary
Median out-of-pocket and insurance costs for 49 high-volume brand-name drugs jumped 79% from 2012 to 2017 in a new analysis of 35m individual insurance claims published in JAMA Network. Competition did not correlate to lower costs.
You may also be interested in...
One More Score: CBO Projects HHS Rebate Proposal Would Boost Part D Spending $170bn
HHS downplays latest attempt to predict “complex behavior changes to a broken system.”
Industry's Drug Pricing Power Is Running On Fumes
Pharma is facing a big headwind in 2019 in the form of diminished drug pricing power. The pricing trend puts net drug prices squarely in the red for most large pharma manufacturers, but US lawmakers aren't likely to be reassured heading into an upcoming hearing on drug pricing.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.